Joanna Moncrieff, a professor of critical and social psychiatry at University College London and an NHS psychiatrist, has ignited a fervent debate within the medical community and beyond regarding the efficacy of antidepressants. Her 2022 paper, The Serotonin Theory of Depression: A Systematic Umbrella Review of the Evidence, published in the journal Molecular Psychiatry, challenged decades of prevailing thought by concluding there was “no evidence” that low levels of serotonin cause depression. As reported by Times UK, this landmark paper has become one of the most widely read scientific studies of recent years, sparking both acclaim and controversy.
Moncrieff, 58, has built a career questioning mainstream psychiatry and its reliance on pharmaceuticals. Her findings, based on 17 major studies, disputed the long-held theory that selective serotonin reuptake inhibitors (SSRIs) cure depression by correcting a chemical imbalance in the brain. This conclusion has unsettled the medical community and patients alike. “I’m not convinced antidepressants have any use,” Moncrieff told reporters. She emphasized that while some people may find SSRIs dampen emotional intensity, they do not address underlying causes of depression, which she attributes largely to social and personal circumstances.
The backlash against Moncrieff was immediate and fierce. Critics accused her of “pill shaming” and undermining public trust in antidepressants, which remain a cornerstone of treatment for millions. Notably, Dr. James Rucker of King’s College London claimed her narrative contributed to patient suicides, a charge Moncrieff vehemently denies. Despite the criticism, she has remained steadfast, arguing that people deserve to understand the potential side effects of SSRIs, such as permanent sexual dysfunction and severe withdrawal symptoms, and should not be shielded from the evidence. Comparing the issue to past medical controversies like thalidomide, Moncrieff stressed the importance of transparency.
The stakes are high. In England alone, 8.7 million people were prescribed antidepressants in 2023, marking a 16% increase over five years. While many patients and practitioners report positive outcomes, Moncrieff argues this reliance on drugs represents a “widespread delusion” driven by pharmaceutical companies and an insecure psychiatric profession. In her latest book, Chemically Imbalanced, she criticizes the notion that emotional distress can be “cured” with a pill and advocates for non-pharmaceutical approaches such as cognitive-behavioral therapy (CBT), exercise, and lifestyle changes.
Moncrieff’s critique extends to the historical origins of antidepressants. First developed by accident in the 1950s, their rise was fueled by marketing rather than definitive scientific proof. Pharmaceutical companies promoted the idea of a serotonin imbalance to justify their products, much like Purdue Pharma did with opioids in the United States—a comparison Moncrieff finds troubling.
Her work has also been scrutinized for alleged methodological weaknesses, with some researchers asserting that her conclusions oversimplify a complex issue. Critics like Sameer Jauhar of King’s College London argue that modern psychiatry acknowledges depression as a multifaceted condition and that serotonin is only one piece of a larger puzzle. However, Moncrieff contends that no compelling evidence supports these alternative theories either, framing them as attempts to sustain a lucrative pharmaceutical model.
The public response has been equally polarized. Some praise Moncrieff for challenging the status quo, while others fear her findings might deter patients from seeking effective treatment. Times UK highlighted the tragic case of Thomas Kingston, whose death in 2022 was linked by his family to an adverse reaction to the SSRI citalopram, underscoring the potential dangers of these medications. Withdrawal symptoms, once downplayed, are now recognized as a significant issue, with studies revealing that one in six patients struggle to quit antidepressants.
Moncrieff’s personal experiences also inform her views. Having suffered from depression as a teenager, she resisted medical intervention and found solace through life changes rather than medication. While acknowledging her experience may not apply universally, she remains skeptical of the medicalization of what she sees as a natural response to adversity.
This debate has far-reaching implications for psychiatry and public health. In recent years, guidelines from the National Institute for Health and Care Excellence (NICE) have shifted toward emphasizing non-drug therapies for mild depression. However, Moncrieff believes these changes reflect the declining profitability of older antidepressants rather than a genuine shift in medical consensus.
Ultimately, Moncrieff’s work challenges us to reconsider the role of medicine in addressing mental health. As she points out, while SSRIs may provide temporary relief, they do not teach people to navigate life’s challenges independently. “For most people, things in their lives will get better or they will come out of whatever it was that was making them low,” she argues. “But if they attribute that to a drug, they don’t learn that in fact these things pass and they might be able to do something about it themselves.”
